不安および鬱病治療市場：現状分析と予測（2021年～2027年）

世界の不安および鬱病治療の市場規模は、予測期間（2021年～2027年）に約3％のCAGRで拡大すると予測されています。急速に発展する新薬と、人々の精神障害の深刻さに対する意識の高まりが、不安および鬱病治療市場の成長を促進しています。

当レポートでは、世界の不安および鬱病治療市場について調査し、市場の現状とともに、薬剤タイプ別、流通チャネル別、疾患タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクション

第2章 調査手法または仮定

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 世界の不安および鬱病治療市場に対するCOVID-19の影響

第6章 世界の不安および鬱病治療市場の収益、2019年～2027年

第7章 薬剤タイプ別の市場洞察

• 抗うつ薬
• 抗けいれん薬
• 非定型抗精神病薬
• ベンゾジアゼピン
• ベータ遮断薬

第8章 流通チャネル別の市場洞察

• 院内薬局
• 小売薬局
• オンライン薬局

第9章 疾患タイプ別の市場洞察

• 大うつ病性障害（MDD）
• OCD
• 恐怖症
• PTSD
• その他

第10章 地域別の市場洞察

• 北米
• 欧州
• アジア太平洋
• その他の地域

第11章 不安および鬱病治療市場の市場力学

• 市場の促進要因
• 市場の課題
• 影響分析

第12章 不安および鬱病治療市場の機会

第13章 不安および鬱病治療市場の動向

第14章 法規制の枠組み

第15章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 企業概要

• GlaxoSmithKline plc
• Pfizer Inc.
• Eli Lilly and Company
• H. Lundbeck A/S
• Forest Laboratories Inc.
• AstraZeneca
• Merck & Company Inc.
• Johnson & Johnson
• Sanofi-Aventis
• Lupin ltd

第19章 免責事項

The global anxiety and depression treatment market is anticipated to grow with an elevated CAGR of around 3% over the forecast period (2021-2027). Anxiety and Depression are the most common mental disorders where the melancholy mood lasts for a long duration. Thus, affects the overall efficiency of the person, and depression is directly linked with stress and anxiety. The long term anxiety is considered one of the symptoms of depression.

The rapidly developing novel drugs and rising awareness about the severity of mental disorders among people contribute to the significant market growth of the anxiety and depression treatment market. The changing lifestyle preferences such as consumption of the substance and problems like insomnia are the major factors contributing to the increasing number of depression cases. Moreover, the increasing unemployment around the globe is also responsible for the increasing stress and anxiety levels among the youths resulting in the increasing demand for better treatment of anxiety and depression. As per the international labor organization, the global unemployment rate is increasing by 6.7% annually.

GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly and Company, H. Lundbeck A/S, Forest Laboratories, Inc., AstraZeneca, Merck & Company, Inc., Johnson & Johnson, and Sanofi-Aventis are some of the prominent players operating in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new varieties of anxiety and depression treatments.

Insights Presented in the Report

"Amongst Drug Type, anti-depressant drug segment holds the major share"

Based on drug types, the anxiety and depression treatment market is segmented into antidepressants, anticonvulsants, atypical antipsychotics, benzodiazepines, and Beta-blockers. The anti-depressant drug class is expected to have significant growth during the forecast period owing to the continuous development and approval of the new medications for the treatment of anxiety and depression. For instance, in April 2022, Lupin Ltd received approval from the US health regulator to market its generic version of Desvenlafaxine extended-release tablets used for treating depression.

"Amongst distribution channels, online channel segment holds the major share"

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online channels. Amongst them, the online pharmacies distribution channel is expected to witness significant growth due to the rising investment in e-pharmacy across the world. However, anxiety and depression drugs are mostly available only through prescription. Thus, doctors are now preferring e-prescriptions to allow patients to get easy access to medicine with the help of e-prescriptions. Countries, like the United Kingdom, are putting more effort into the implementation of e-prescriptions. For instance, the electronic prescription service (EPS) will be rolled out across England after a trial run in 60 GP practices and hundreds of pharmacies, in 2019. National Health Service (NHS) aimed to save USD 373 million in the next two years.

Amongst disorder types, the major depressive disorder segment holds the major share"

Based on the disorder type, the market is segmented into major depressive disorder (MDD), OCD, phobia, PTSD, and others. Among them, the market for major depressive disorder is expected to witness significant growth. The growth of the segmented is mainly attributed to the increasing level of workplace stress and the number of suffering people along with a lack of the appropriate knowledge about the severity of the diseases leads to the development of stress into major depressive disorder. According to the American workplace and NIOSH Reports, 80% of workers feel stress on the job among them 40% of workers reported their job was very or extremely stressful.

"North America represents one of the largest markets of Anxiety and Depression Treatment market"

For a better understanding of the market dynamics of the Anxiety and Depression Treatment market, a detailed analysis was conducted for different regions across the globe including North America (U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. In 2020, North America accounted for the majority share in the market. The increasing number of awareness programs by the governments is driving the market for anxiety and depression disorders in the region. Canada, for instance, launched the mental illness awareness week in October 2021 to educate people about mental health and its effects.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Customization Options:

The global anxiety and depression treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stake Holders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Anxiety and Depression Treatment Market
• 2.2. Research Methodology of the Anxiety and Depression Treatment Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Anxiety and Depression Treatment Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET COVID-19 IMPACT

6 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY DRUG TYPE

• 7.1. Antidepressants
• 7.2. Anticonvulsants
• 7.3. Atypical antipsychotics
• 7.4. Benzodiazepines
• 7.5. Beta-blockers

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Hospital Pharmacies
• 8.2. Retail Pharmacies
• 8.3. Online Pharmacies

9 MARKET INSIGHTS BY DISORDER TYPE

• 9.1. Major Depressive Disorder (MDD)
• 9.2. OCD
• 9.3. Phobia
• 9.4. PTSD
• 9.5. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. United States
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. France
  • 10.2.3. U.K.
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia Pacific
• 10.4. Rest of World

11 ANXIETY AND DEPRESSION TREATMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ANXIETY AND DEPRESSION TREATMENT MARKET OPPORTUNITIES

13 ANXIETY AND DEPRESSION TREATMENT MARKET TRENDS

14 LEGAL & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. GlaxoSmithKline plc
• 18.2. Pfizer Inc.
• 18.3. Eli Lilly and Company
• 18.4. H. Lundbeck A/S
• 18.5. Forest Laboratories Inc.
• 18.6. AstraZeneca
• 18.7. Merck & Company Inc.
• 18.8. Johnson & Johnson
• 18.9. Sanofi-Aventis
• 18.10. Lupin ltd

19 DISCLAIMER